JPMorgan Maintains Neutral Rating on Agios
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
After Agios announced that the FDA has approved Aqvesme for the treatment of anemia in adults with alpha- or beta-thalassemia, JPMorgan analyst Tessa Romero notes that the U.S. brand name is not Pyrukynd due to the REMS program that is specific for the thalassemia indication. The firm, which foresees a slower, gradual launch given the phase 3 thalassemia data, complexities of the patient population and the REMS to mitigate the risk of HCI, looks toward the firm's Healthcare Conference as a venue to further discuss the anticipated launch trajectory for Aqvesme and the outlook for 2026. JPMorgan has a Neutral rating on Agios shares.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like AGIO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is 36.38 USD with a low forecast of 25.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 28.310
Low
25.00
Averages
36.38
High
62.00
Current: 28.310
Low
25.00
Averages
36.38
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
- Market Focus: UiPath Inc. announced it will join the S&P Midcap 400 Index on January 2, 2026, replacing Synovus Financial Corp., a move expected to enhance the company's visibility and investor confidence.
- Stock Price Surge: Following this announcement, UiPath shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism regarding its future performance.
- FDA Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating anemia in adults with alpha- or beta-thalassemia, although its stock fell 1.4%, this approval could pave the way for future sales growth.
- Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% in after-hours trading, indicating the company's confidence in its value and potentially attracting more investor interest.
Continue Reading
HC Wainwright Raises Agios Price Target to $62
- Price Target Increase: HC Wainwright & Co. raised the price target for Agios Pharmaceuticals from $48 to $62, with analyst Emily Bodnar maintaining a Buy rating, indicating strong confidence in the company's future growth prospects.
- Market Performance: Agios Pharmaceuticals shares closed at $29.17 on Wednesday, suggesting that despite the price target increase, the current stock price remains undervalued compared to the new target, reflecting market skepticism about its potential.
- Competitive Analysis: In contrast to Agios's price target increase, Lexaria Bioscience's target was cut to $1.5, highlighting significant differences in market outlooks for various biotech companies.
- Capital One Outlook: BTIG raised the price target for Capital One Financial from $264 to $308, with analyst Vincent Caintic maintaining a Buy rating, reflecting optimism about the financial institution's future performance.
Continue Reading